Leerink Partners upgraded Intellia Therapeutics (NASDAQ: NTLA) from Market Perform to Outperform with a price target of $32.00 on valuation.
Analyst Michael Schmidt commented, "We believe the current valuation, close to the mid-point of the in IPO range of $16-$18, represents an attractive entry point to own one of... More